riomet Drug Patent Profile
✉ Email this page to a colleague
When do Riomet patents expire, and what generic alternatives are available?
Riomet is a drug marketed by Ranbaxy and Sun Pharm and is included in two NDAs. There is one patent protecting this drug and one Paragraph IV challenge.
The generic ingredient in RIOMET is metformin hydrochloride. There are forty-nine drug master file entries for this compound. Eighty-five suppliers are listed for this compound. Additional details are available on the metformin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Riomet
A generic version of riomet was approved as metformin hydrochloride by ATLAS PHARMS LLC on January 24th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for riomet?
- What are the global sales for riomet?
- What is Average Wholesale Price for riomet?
Summary for riomet
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 164 |
Clinical Trials: | 41 |
Patent Applications: | 579 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for riomet |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for riomet |
What excipients (inactive ingredients) are in riomet? | riomet excipients list |
DailyMed Link: | riomet at DailyMed |
![riomet drug patent expirations Drug patent expirations by year for riomet](/p/graph/s/t/riomet-patent-expirations.png)
![Drug Prices for riomet](/p/graph/drug-price/riomet.png)
![Drug Sales Revenue Trends for riomet](/p/graph/drug-sales-revenues/riomet.png)
Recent Clinical Trials for riomet
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Washington State University | Early Phase 1 |
National Institutes of Health (NIH) | Early Phase 1 |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Early Phase 1 |
Pharmacology for riomet
Drug Class | Biguanide |
Paragraph IV (Patent) Challenges for RIOMET
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
RIOMET | Oral Solution | metformin hydrochloride | 500 mg/5 mL | 021591 | 1 | 2018-02-02 |
US Patents and Regulatory Information for riomet
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ranbaxy | RIOMET | metformin hydrochloride | SOLUTION;ORAL | 021591-001 | Sep 11, 2003 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sun Pharm | RIOMET ER | metformin hydrochloride | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 212595-001 | Aug 29, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for riomet
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ranbaxy | RIOMET | metformin hydrochloride | SOLUTION;ORAL | 021591-001 | Sep 11, 2003 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for riomet
See the table below for patents covering riomet around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Poland | 365135 | ⤷ Sign Up | |
Russian Federation | 2003104808 | ⤷ Sign Up | |
China | 1635881 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for riomet
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1506211 | PA2014026 | Lithuania | ⤷ Sign Up | PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116 |
1506211 | 122014000070 | Germany | ⤷ Sign Up | PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, WIE DURCH DAS GRUNDPATENT GESCHUETZT; REGISTRATION NO/DATE: EU/1/13/900 20140116 |
1261586 | C01261586/02 | Switzerland | ⤷ Sign Up | PRODUCT NAME: SAXAGLIPTIN UND METFORMIN; NAT. REGISTRATION NO/DATE: SWISSMEDIC 62040 20120329 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |